Disease Focus

Alzheimers Disease

Gene Solutions’ scientists accelerated their pace in the field of Alzheimer’s target development and lead design by building upon the Parkinson’s body of knowledge, validated processes, and cell-based assays.  Moving to, qualifying, and verifying a different region of interest in mitochondrial DNA, the company has identified a number of implicated codons for Alzheimer’s Disease.  These formed the basis for a number of current patents pending.

Our Alzheimer’s platform further enhances the company’s leadership position in rational drug design in both the USA and UK facilities utilizing the company’s novel platform approach to mitochondrial CNS disorders, with the UK being the locus of control for both molecular modeling and final lead construction and registration compound characterization and archiving.  The company has fortified its reach by partnering with leading academic institutions for independent and objective assay development and target/lead binding and validation.

While being a partner of choice for pharma and biotech companies interested in enhancing their knowledge, or genuine pursuit of funded discovery research, as well as molecular diagnostics in the field of Alzheimers, Gene Solutions remains open for all opportunities in this supremely large patient population indication – and in the environment where existing clinical studies for amyloid and plaques has proven increasingly frustrating and unfulfilling.  We have a better way; possibly the only way, and we believe our research can help.

Parkinsons Disease

Gene Solutions’ Parkinson’s scope of knowledge, validated tissue, brain and blood molecular diagnostic processes, and cell-based assays stand at the forefront of novel discovery and preclinical approaches.  The company’s patented implicated mitochondrial DNA codons serve as novel targets for the company’s small molecule and small peptide chemists.  Both the UK and USA-based research groups are highly integrated and motivated toward these potential curative therapies.

As with Alzheimers’, the UK remains the locus of control for molecular modeling, final lead construction, and registration compound characterization and archiving.  The UK team partners with leading academic institutions for independent and objective binding assay development and validation.

While being a partner of choice for pharma and biotech companies interested in enhancing their knowledge, or aggressive pursuit of contract and milestone-driven discovery research, as well as molecular diagnostics in the field of Parkinsons, Gene Solutions welcomes opportunities in this frustrating indication – and in the environment where existing clinical studies for alternative approaches has proven difficult above reproach.  We think have a better way; possibly the only way, and we believe our research can help.